Mike Romanos Appointed as CEO of Crescendo Biologics
Limited (Crescendo) today announces the appointment of
Executive Officer. Dr Romanos has been Chief Scientific Officer of the
development of its proprietary antibody fragment technologies.
During this time, the company has made significant progress in the
establishment of its team and its technology platforms. This has included the
establishment of a colony of engineered mice completely devoid of endogenous
antibody polypeptides, announced in September. The proprietary ‘triple
knockout’ mice are believed to be unique and have the immunoglobulin heavy
chain (IgH), kappa light chain and lambda light chain loci all functionally
silenced by large-scale genomic deletion.
Dr Romanos has more than 23 years’ biotech and pharma industry experience
and within the last 10 years has held senior global positions leading major
parts of GlaxoSmithKline Discovery.
growing maturity of Crescendo and the progress the company has made under
Mike’s leadership. We have seen significant advances in the technology
platform and I am sure that with Mike now taking on the CEO position
Crescendo will deliver real value from its world class, proprietary
technology platforms and grow to become a leader in next-generation antibody
About Crescendo Biologics Ltd
Crescendo Biologics will apply highly innovative antibody fragment
technologies to the development of new targeted therapeutics. The Crescendo
transgenic mouse platform under development has the potential to rapidly and
predictably generate high-affinity human heavy chain antibodies that readily
yield VH fragments that have no requirement for humanisation. This is
combined with a powerful in vitro ribosome display technology which offers
significant advantages over existing approaches in antibody optimisation. VH
fragments provide great flexibility as a starting point for the development
of new targeted therapeutics combining the specificity and binding affinity
of antibodies with certain desirable characteristics of small molecules.
Crescendo’s technologies were invented by scientists at the Babraham
funding from leading life sciences investors, Sofinnova Partners with Aitua,
Avlar BioVentures and the Rainbow Seed Fund also participating.
Contacts Mike Romanos/Amanda Bettison Crescendo Biologics Tel: +44(0)1223-497140 Email: email@example.com Chris Gardner Citigate Dewe Rogerson Tel: +44(0)207-638-9571 Email: firstname.lastname@example.org
SOURCE Crescendo Biologics